Lancashire and South Cumbria
Formulary
Formulary
6 Endocrine system
06-06-01 Calcitonin and parathyroid hormone
| Abaloparatide |
|
Formulary
|
Osteoporosis after menopause. |
 NICE TA991: Abaloparatide for treating osteoporosis after menopause |
|
| Teriparatide |
|
Formulary
|
Injection 750micrograms/3mL prefilled pen For specialist use only in accordance with NICE TA guidance (women) or NHS England commissioning policy (men).
|
 NHSE: Clinical Commissioning Policy: Teriparatide for Osteoporosis in Men (Adults) NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
|
|
Links
- Diabetes UK: Diabetes when you’re unwell
- LSCMMG: Diabetes - Choice of Safety Pen Needles and Lancets
- LSCMMG: Diabetes - Pen Needles/Lancets
- LSCMMG: Diabetes - Position Statement Safety Needles and Safety Lancets
- LSCMMG: Diabetes Guideline for antihyperglycaemic therapy in adults with type 2 diabetes
- LSCMMG: Diabetes: Recommended meters, strips and devices
LSCMMG: GLP-1 patient contract- LSCMMG: Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus
- LSCMMG: Trans Female Gender Dysphoria Information Sheet
- LSCMMG: Trans Male Gender Dysphoria Information Sheet
- MHRA: Diabetes and driving
- NHSE guidance to primary care about unregulated providers who supply hormone medications to children and young people for gender incongruence
- NHSE: Clinical Commissioning Policy: Teriparatide for Osteoporosis in Men (Adults)
- NICE NG17: Type 1 diabetes in adults: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
- NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
- NICE TA625: Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal)
- NICE TA991: Abaloparatide for treating osteoporosis after menopause
- Osteoporosis Guideline (NOGG 2021)